Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL Study: Severe Asthma Patient Characterization
NCT02293265Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2014
- Primary completion
- May 2015
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial, sponsored by GSK. Primary endpoint: Number of severe asthma patients eligible for one or more biologic treatments for asthma at Day 1. Started Dec 2014; status: completed.
Beyond the preview
Go deeper on NCT02293265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293265.